^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Genito-urinary Cancer

    Apply
    Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy (NCT04963153)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    07/07/2022
    Primary completion :
    09/01/2025
    Completion :
    09/01/2025
    PD-L1 • FGFR2 • NECTIN4
    |
    PD-L1 expression
    |
    Balversa (erdafitinib) • Padcev (enfortumab vedotin-ejfv)
    Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE) (NCT06041503)
    Phase 2
    National Cancer Institute (NCI)
    Not yet recruiting
    Last update posted :
    02/24/2025
    Initiation :
    02/27/2025
    Primary completion :
    10/01/2027
    Completion :
    10/01/2028
    CD4
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)
    A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (NCT06842498)
    Phase 2
    FibroGen
    Not yet recruiting
    Last update posted :
    02/24/2025
    Initiation :
    03/01/2025
    Primary completion :
    09/30/2027
    Completion :
    09/30/2027
    CD46
    |
    FG-3246
    Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer (NCT04628767)
    Phase 2/3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/12/2021
    Primary completion :
    09/30/2027
    Completion :
    09/30/2027
    CD4
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • doxorubicin hydrochloride • methotrexate • vinblastine • Neulasta (pegfilgrastim) • Fulphila (pegfilgrastim-jmdb) • Neupogen (filgrastim) • Udenyca (pegfilgrastim-cbqv) • Ziextenzo (pegfilgrastim-bmez) • liposomal gemcitabine (FF-10832) • methotrexate IV
    Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors (NCT03866382)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    05/13/2019
    Primary completion :
    02/28/2026
    Completion :
    02/28/2026
    PD-L1 • CD4
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer (NCI-2018-01054) (NCT03360721)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    03/06/2018
    Primary completion :
    04/30/2027
    Completion :
    04/30/2027
    PTEN
    |
    AR overexpression • AR expression • AR-V7 expression
    |
    abiraterone acetate • prednisone • apalutamide • Yonsa (abiraterone acetate)
    A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers (NCT04708470)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    10/05/2021
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    PD-L1 • CD4
    |
    PD-L1 negative
    |
    Jingzhuda (entinostat) • bintrafusp alfa (M7824) • PDS01ADC
    Precision-Based Genomics in Prostate Cancer (NCT04706663)
    Phase N/A
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    09/14/2021
    Primary completion :
    06/30/2026
    Completion :
    06/30/2027
    TMB • RB1 • MLH1 • MSH6 • MSH2 • CDK12 • RAD51 • BRIP1 • RAD50 • SPOP • EPCAM
    |
    TMB-H
    Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors (NCT04119024)
    Phase 1
    Jonsson Comprehensive Cancer Center
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    11/27/2019
    Primary completion :
    10/01/2025
    Completion :
    10/01/2026
    BRAF
    |
    BRAF mutation • BRAF V600
    |
    cyclophosphamide • fludarabine IV • Imunace (teceleukin) • MB-101 • cyclophosphamide intravenous
    Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health (AMPLIFY) (NCT04000880)
    Phase N/A
    University of Alabama at Birmingham
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    03/04/2020
    Primary completion :
    04/01/2025
    Completion :
    04/01/2025
    IL6 • TNFA • CRP
    Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies (20-C-0012) (NCT04235777)
    Phase 1
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    07/13/2020
    Primary completion :
    12/01/2027
    Completion :
    12/01/2027
    CD4
    |
    PD-L1 expression
    |
    bintrafusp alfa (M7824) • PDS01ADC
    An Exploratory Evaluation of Biomarkers in Blister Fluid in Healthy Volunteers and Irradiated Skin (NCT00923104)
    Phase N/A
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    02/21/2025
    Initiation :
    04/23/2009
    IL6 • TNFA • IL1B • MMP1
    Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma (NCT05155033)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    08/18/2022
    Primary completion :
    09/01/2026
    Completion :
    09/01/2027
    PD-L1
    |
    Keytruda (pembrolizumab) • Proleukin (aldesleukin)
    T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy (NCT05361798)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    06/12/2023
    Primary completion :
    08/01/2026
    Completion :
    12/01/2026
    PD-L1
    |
    PDS01ADC
    A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors (HERTHENA-PanTumor01) (NCT06172478)
    Phase 2
    Daiichi Sankyo
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    02/26/2024
    Primary completion :
    06/30/2025
    Completion :
    04/30/2026
    ERBB3
    |
    patritumab deruxtecan (U3-1402)
    Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes (NCI-2017-02296) (NCT03375307)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    11/03/2020
    Primary completion :
    12/16/2025
    Completion :
    12/16/2025
    TP53 • TMB • ABL1 • MSI • STK11 • NPM1 • POLE • CCND1 • MLH1 • MSH6 • MSH2 • ATRX • CHEK2 • SMARCB1 • RAD51 • POLD1 • CHEK1 • BARD1 • FANCL • BRD4 • DOT1L • FANCE • FANCG • IKBKE • FANCC
    |
    FANCG mutation
    |
    Lynparza (olaparib)
    HER2 and LA/mUC: A Multi-country Chart Review Cohort Study (NCT05902494)
    Phase N/A
    Seagen Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    06/29/2023
    Primary completion :
    09/30/2025
    Completion :
    09/30/2025
    HER-2
    |
    HER-2 expression
    Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (ARCITECT) (NCT05928806)
    Phase 2
    Michael B. Atkins, MD
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    09/25/2023
    Primary completion :
    10/10/2025
    Completion :
    10/12/2026
    CD4
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • balstilimab (AGEN2034) • botensilimab (AGEN1181)
    A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients with Prostate Cancer (OncoACP-3) (NCT06840535)
    Phase 1
    Philogen S.p.A.
    Not yet recruiting
    Last update posted :
    02/21/2025
    Initiation :
    02/01/2025
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    FOLH1
    |
    FOLH1 expression
    Study to Determine Possible Effects of Apalutamide, Compared to Placebo, on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer (INT22-09-01) (NCT05521698)
    Phase 1
    National Cancer Institute (NCI)
    Not yet recruiting
    Last update posted :
    02/21/2025
    Initiation :
    04/23/2025
    Primary completion :
    01/15/2027
    Completion :
    07/15/2027
    EGFR • FGFR3 • AR • CD8 • PD-1 • SLAMF6 • ADAR • TCF7
    |
    EGFR expression
    |
    apalutamide
    Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer (NCT00050752)
    Phase N/A
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    02/24/2003
    FH
    |
    FH mutation
    Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer (NCT05730712)
    Phase 2
    Mayo Clinic
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    03/08/2024
    Primary completion :
    10/01/2025
    Completion :
    10/01/2025
    NRG1
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • Xtandi (enzalutamide) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)
    A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE) (NCT03748641)
    Phase 3
    Janssen Research & Development, LLC
    Active, not recruiting
    Last update posted :
    02/20/2025
    Initiation :
    01/25/2019
    Primary completion :
    10/08/2021
    Completion :
    03/19/2027
    HRD • BRCA
    |
    Zejula (niraparib) • abiraterone acetate • prednisone • Akeega (abiraterone/niraparib)
    A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 (KEYNOTE-D78) (NCT04879329)
    Phase 2
    Seagen Inc.
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    05/03/2022
    Primary completion :
    11/30/2026
    Completion :
    05/30/2028
    HER-2
    |
    HER-2 expression
    |
    Keytruda (pembrolizumab) • Aidixi (disitamab vedotin)
    Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 (KEYNOTE-D74) (NCT05911295)
    Phase 3
    Seagen Inc.
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    09/22/2023
    Primary completion :
    06/30/2026
    Completion :
    04/30/2029
    HER-2
    |
    HER-2 expression
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • gemcitabine • Aidixi (disitamab vedotin)
    INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors (NCT04580485)
    Phase 1
    Incyte Corporation
    Completed
    Last update posted :
    02/18/2025
    Initiation :
    02/03/2021
    Primary completion :
    01/22/2024
    Completion :
    01/22/2024
    CD8
    |
    Zynyz (retifanlimab-dlwr) • INCB106385
    Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy (NCT06439836)
    Phase 1
    National Cancer Institute (NCI)
    Not yet recruiting
    Last update posted :
    02/18/2025
    Initiation :
    02/21/2025
    Primary completion :
    06/01/2027
    Completion :
    06/01/2027
    PD-L1 • CD68 • CRP
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • emavusertib (CA-4948)
    A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors (ST101-101) (NCT04478279)
    Phase 1/2
    Sapience Therapeutics
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    07/01/2020
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    BRAF
    |
    HR positive • BRAF mutation
    |
    temozolomide • Xtandi (enzalutamide) • abiraterone acetate • lucicebtide (ST101)
    Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers (NCT03190174)
    Phase 1/2
    Sarcoma Oncology Research Center, LLC
    Completed
    Last update posted :
    02/17/2025
    Initiation :
    08/24/2017
    Primary completion :
    12/01/2021
    Completion :
    12/02/2021
    MSI
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • sirolimus • Fyarro (nanoparticle albumin-bound rapamycin)
    A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005) (LITESPARK-005) (NCT04195750)
    Phase 3
    Merck Sharp & Dohme LLC
    Active, not recruiting
    Last update posted :
    02/17/2025
    Initiation :
    02/27/2020
    Primary completion :
    04/15/2024
    Completion :
    09/17/2026
    PD-L1
    |
    everolimus • Welireg (belzutifan)
    Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC (NCT06222593)
    Phase 1/2
    State University of New York at Buffalo
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    10/01/2024
    Primary completion :
    07/01/2026
    Completion :
    07/01/2027
    AR • KLK2
    |
    AR expression • KLK2 expression
    |
    sunitinib • bicalutamide
    A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors (BG-68501-101) (NCT06257264)
    Phase 1
    BeiGene
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    03/11/2024
    Primary completion :
    02/28/2028
    Completion :
    02/28/2028
    HER-2
    |
    HER-2 negative
    |
    fulvestrant
    Study of Oral MRT-2359 in Selected Cancer Patients (MRT-2359-001) (NCT05546268)
    Phase 1/2
    Monte Rosa Therapeutics, Inc
    Recruiting
    Last update posted :
    02/17/2025
    Initiation :
    10/12/2022
    Primary completion :
    05/01/2026
    Completion :
    11/01/2027
    MYC • MYCN
    |
    MYCN amplification • MYC expression
    |
    Xtandi (enzalutamide) • fulvestrant • MRT-2359
    A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (CHAMP) (NCT04709276)
    Phase 2
    Andrew J. Armstrong, MD
    Recruiting
    Last update posted :
    02/14/2025
    Initiation :
    06/07/2021
    Primary completion :
    12/01/2025
    Completion :
    06/01/2028
    TP53 • PTEN • RB1 • SYP
    |
    LDH elevation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • cabazitaxel
    Study on the Safety, Tolerability, and Preliminary Efficacy of 161Tb-NYM032 in Patients with Metastatic Castration-Resistant Prostate Cancer (NCT06827080)
    Phase 1/2
    Zhengguo Chen
    Not yet recruiting
    Last update posted :
    02/14/2025
    Initiation :
    02/11/2025
    Primary completion :
    12/01/2026
    Completion :
    12/01/2026
    FOLH1
    |
    FOLH1 expression
    A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors (HFB-200603-01) (NCT05789069)
    Phase 1
    HiFiBiO Therapeutics
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    05/09/2023
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    BRAF
    |
    BRAF V600
    |
    Tevimbra (tislelizumab-jsgr) • HFB200603
    Savolitinib vs. Sunitinib in MET-driven PRCC. (SAVOIR) (NCT03091192)
    Phase 3
    AstraZeneca
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    07/25/2017
    Primary completion :
    08/18/2019
    Completion :
    12/31/2025
    VHL
    |
    VHL mutation
    |
    sunitinib • Orpathys (savolitinib)
    A Study of the C-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced And/or Metastatic Solid Tumors Known to Express C-Kit (NCT06805825)
    Phase 1
    Novelty Nobility, Inc.
    Recruiting
    Last update posted :
    02/13/2025
    Initiation :
    02/03/2025
    Primary completion :
    08/30/2027
    Completion :
    12/31/2027
    KIT
    |
    NN3201
    Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (NCT02496208)
    Phase 1
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    07/22/2015
    Primary completion :
    09/30/2026
    Completion :
    09/30/2026
    PD-L1
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)
    Targeted Alpha Therapy with 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). (NCT05219500)
    Phase 2
    Fusion Pharmaceuticals Inc.
    Active, not recruiting
    Last update posted :
    02/13/2025
    Initiation :
    12/16/2021
    Primary completion :
    04/30/2025
    Completion :
    07/31/2025
    MSI • BRCA
    |
    BRCA mutation
    |
    FPI-2265
    Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma (ETCTN 10183) (NCT03854474)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/12/2025
    Initiation :
    11/18/2019
    Primary completion :
    06/30/2025
    Completion :
    06/30/2025
    PD-L1 • PD-1
    |
    EZH2 mutation
    |
    Keytruda (pembrolizumab) • cisplatin • Tazverik (tazemetostat) • Pembroria (pembrolizumab biosimilar)